Significant Wealth Partners LLC Invests $248,000 in Humana Inc. (NYSE:HUM)

Significant Wealth Partners LLC bought a new position in Humana Inc. (NYSE:HUMFree Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 541 shares of the insurance provider’s stock, valued at approximately $248,000.

A number of other institutional investors have also recently bought and sold shares of HUM. Ameriprise Financial Inc. raised its stake in Humana by 35.9% during the third quarter. Ameriprise Financial Inc. now owns 1,523,835 shares of the insurance provider’s stock worth $741,409,000 after purchasing an additional 402,559 shares during the period. AQR Capital Management LLC raised its position in shares of Humana by 39.3% in the 3rd quarter. AQR Capital Management LLC now owns 681,868 shares of the insurance provider’s stock worth $331,743,000 after buying an additional 192,546 shares during the period. Quadrature Capital Ltd boosted its holdings in Humana by 814.5% in the third quarter. Quadrature Capital Ltd now owns 181,787 shares of the insurance provider’s stock valued at $88,448,000 after acquiring an additional 161,909 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in Humana by 2,659.2% during the third quarter. Adage Capital Partners GP L.L.C. now owns 152,860 shares of the insurance provider’s stock valued at $74,369,000 after acquiring an additional 147,320 shares during the period. Finally, International Assets Investment Management LLC grew its position in Humana by 32,648.4% during the fourth quarter. International Assets Investment Management LLC now owns 134,596 shares of the insurance provider’s stock valued at $61,619,000 after acquiring an additional 134,185 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Stock Down 0.9 %

Shares of Humana stock opened at $325.30 on Tuesday. Humana Inc. has a 1-year low of $299.23 and a 1-year high of $541.21. The company has a market capitalization of $39.25 billion, a PE ratio of 16.41, a P/E/G ratio of 1.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59. The business has a 50-day moving average of $330.09 and a 200-day moving average of $399.70.

Humana (NYSE:HUMGet Free Report) last issued its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The business had revenue of $26.46 billion during the quarter, compared to analysts’ expectations of $25.47 billion. During the same period in the prior year, the company posted $1.62 EPS. The company’s revenue for the quarter was up 17.9% on a year-over-year basis. As a group, equities analysts forecast that Humana Inc. will post 16.06 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be given a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.09%. The ex-dividend date of this dividend is Friday, June 28th. Humana’s payout ratio is currently 17.86%.

Insider Buying and Selling

In related news, Director Jorge S. Mesquita acquired 545 shares of Humana stock in a transaction on Tuesday, February 20th. The shares were purchased at an average cost of $367.09 per share, for a total transaction of $200,064.05. Following the purchase, the director now directly owns 2,578 shares of the company’s stock, valued at approximately $946,358.02. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.29% of the company’s stock.

Analyst Upgrades and Downgrades

HUM has been the topic of several research analyst reports. TheStreet lowered Humana from a “b” rating to a “c+” rating in a research note on Monday, January 8th. Oppenheimer restated an “outperform” rating and issued a $630.00 price target on shares of Humana in a report on Wednesday, January 17th. Mizuho decreased their price objective on shares of Humana from $550.00 to $400.00 and set a “buy” rating for the company in a research note on Friday, January 26th. TD Cowen dropped their price objective on shares of Humana from $427.00 to $396.00 and set a “buy” rating for the company in a research report on Tuesday, April 2nd. Finally, Stephens reduced their target price on shares of Humana from $550.00 to $430.00 and set an “overweight” rating on the stock in a report on Friday, January 26th. Eleven investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $454.63.

Read Our Latest Analysis on HUM

Humana Profile

(Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Further Reading

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMFree Report).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.